Drug
Ramantamig clinical trials
Also written JNJ-79635322.
- studies test it
- 7
- open now
- 6
- in phase 3
- 3
- first study started
- 2022
Keep track of what changes. Save the ramantamig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
7 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
Janssen Research & Development, LLC (6) · University of Heidelberg Medical Center (1)
Often tested with
Tested in the same studies.
Talquetamab (2) · Teclistamab (1) · Dexamethasone (1) · Lenalidomide (1) · Bortezomib (1)
Studies
Open first, then newest update. How each study uses ramantamig is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingPhase 3Janssen Research & Development, LLCNCT07665450Written as Ramantamig
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRecruitingPhase 1Janssen Research & Development, LLCNCT05652335Written as JNJ-79635322
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingPhase 2Janssen Research & Development, LLCNCT06500884Written as Ramantamig
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT07518186Written as JNJ-79635322
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT07258511Written as JNJ-79635322
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingPhase 2University of Heidelberg Medical CenterNCT05695508Written as JNJ-79635322
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT07266441Written as JNJ-79635322
Given in every arm · 2 — ramantamig is usual care beside what is tested
- A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Janssen Research & Development, LLCNCT07589634Written as Ramantamig
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingPhase 1Janssen Research & Development, LLCNCT06768489Written as JNJ-79635322
Codes
What other systems call ramantamig · ClinicalTrials.gg INT017156
- UNII (FDA) L97FGF546QRAMANTAMIGOne source FDA
- NCI Thesaurus C216004RamantamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L97FGF546Q | RAMANTAMIG | One source FDA |
| NCI Thesaurus | C216004 | Ramantamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.